Physician profile
Franck A Belibi
NPI 1831211069
$2,982.09
in general payments reported to CMS, 2019-2025
31 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $338 · 2021: $515 · 2022: $541 · 2023: $389 · 2024: $321 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $664.81 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Otsuka America Pharmaceutical, INC. | $261.08 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $247.51 | 2022-2023 | |
| Amgen INC. | $222.45 | 2024-2025 | Krystexxa |
| Novo Nordisk INC | $206.44 | 2019-2025 | Ozempic |
| Horizon Therapeutics Plc | $204.99 | 2022-2023 | Krystexxa |
| Indivior INC. | $202.53 | 2019-2023 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $130.17 | 2019-2025 | Breztri |
| Lilly USA, LLC | $116.35 | 2019-2024 | Mounjaro |
| Orexo US, INC. | $78.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $70.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.41 | 2020-2022 | |
| Amarin Pharma, INC. | $53.12 | 2019 | |
| Xeris Pharmaceuticals, INC. | $48.05 | 2021-2025 | Gvoke Hypopen |
| Pfizer INC. | $47.70 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $47.46 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $41.12 | 2020-2021 | |
| Redhill Biopharma INC. | $31.61 | 2021 | |
| Glaxosmithkline, LLC. | $27.21 | 2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $27.16 | 2024 | |
| Phadia US INC. | $23.37 | 2024 | Immunocap |
| Abbott Laboratories | $22.46 | 2021 | |
| Zealand Pharma US, INC. | $20.79 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.08 | 2021 | |
| Vifor Pharma, INC. | $17.91 | 2022 | |
| Quidel Corporation | $16.46 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.15 | 2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $15.37 | 2022 | |
| Uswm, LLC | $14.62 | 2021 | |
| Hologic Sales and Service, LLC | $12.26 | 2019 | |
| Alfasigma USA, INC. | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franck Belibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.